-
04:34:36 PM
Sign in with email
Forgot your password?
Register with email
Account Verification

TSOI Stock News

10/03/22 9:00 AM
OTC : TSOI
Therapeutic Solutions International Identifies CD103 Expressing Dendritic Cells and Exosomes Thereof as Novel Mechanism for JadiCell Mesenchymal Stem Cell Mediated Lung Protection
Therapeutic Solutions International announced today new data suggesting that therapeutic effects of its universal donor stem cell product are mediated in part through CD103 expressing dendritic cells. Therapeutic Solutions International is currently running a Phase III clinical trial using JadiCells in the treatment of COVID-19 associated ARDS.
RHEA-AI
neutral
09/20/22 9:00 AM
OTC : TSOI
clinical trial
Therapeutic Solutions International Secures Financing to Complete Current Phase III Stem Cell Clinical Trial
Therapeutic Solutions International, a clinical stage regenerative medicine and immunotherapy company, announced today it has entered into an agreement with GHS Investments, LLC to purchase up to $10,000,000 of Registered Common Stock. "This financing will allow the acceleration of our current Phase III clinical trial assessing efficacy of JadiCells, a...
RHEA-AI
neutral
09/19/22 9:00 AM
OTC : TSOI
clinical trial
Therapeutic Solutions International Spin-Off Company Campbell Neurosciences Announces Successful Preclinical Studies of CampbellCell for Treatment of Bipolar Disorder
Therapeutic Solutions International announced positive data and filing of a patent covering the use of CampbellCell for treatment of Bipolar Disorder by the Company' s suicide prevention based spin-off Campbell Neurosciences. In a series of animal experiments using an established animal model of bipolar disorder, superior inhibition of behavioral...
RHEA-AI
neutral
09/12/22 9:00 AM
OTC : TSOI
Therapeutic Solutions International Develops Post JadiCell Maintenance Therapy for Chronic Obstructive Pulmonary Disease (COPD)
Therapeutic Solutions International announced today data and patent filing on a new approach to treating chronic obstructive pulmonary disease. Therapeutic Solutions International currently has an ongoing Phase III clinical trial for COVID-19 induced Acute Respiratory Distress Syndrome and has been granted an IND number by the FDA for treatment of...
RHEA-AI
neutral
08/29/22 9:00 AM
OTC : TSOI
Therapeutic Solutions International Develops Gene Silencing Therapy for Acute Respiratory Distress Syndrome
Therapeutic Solutions International announced today data and filing of a patent covering the use of" gene silencing" in treatment of Acute Respiratory Distress Syndrome, a leading cause of death in emergency rooms. The Company currently is running a Phase III trial treating COVID-19 induced ARDS but has requested permission from the FDA to expand to ARDS...
RHEA-AI
neutral
08/25/22 9:00 AM
OTC : TSOI
clinical trial
Therapeutic Solutions International Files with FDA to Expand ongoing Phase III Clinical Trial to Include All Causes of Acute Respiratory Distress Syndrome
Therapeutic Solutions International announced today filing with the Food and Drug Administration an amendment to its currently open Phase III clinical trial requesting expansion of eligible patients with all patients suffering from Acute Respiratory Distress Syndrome regardless of cause. "In my opinion as a physician, as well as our Scientific...
RHEA-AI
neutral
08/12/22 9:00 AM
OTC : TSOI
Therapeutic Solutions International Reports Superior Efficacy of ApoptoCyte(TM) on Chronic Obstructive Pulmonary Disease Model Compared to Conventional Stem Cell Approaches
Therapeutic Solutions International announced today new data demonstrating superior effects of the Company' s ApoptoCyte(TM) procedure treated JadiCell(TM) product compared to other stem cells in treating an animal model of Chronic Obstructive Pulmonary Disease. James Veltmeyer, Chief Medical Officer of the Company, and co-inventor of both patents." The...
RHEA-AI
neutral
07/28/22 9:00 AM
OTC : TSOI
Therapeutic Solutions International Creates Disease Specific Therapeutic Platform Based on Gene Editing/Engineering of Inducible Pluripotent Stem Cells
Therapeutic Solutions International reported the successful generation of gene-edited and/or gene-modified regenerative cells possessing mixtures of properties between mesenchymal stem cells and tolerance inducing immune cells. James Veltmeyer, Chief Medical Officer of the Company." Utilizing iPSC technology, we have been able to generate...
RHEA-AI
neutral
07/18/22 9:00 AM
OTC : TSOI
clinical trialcovid-19
Therapeutic Solutions International Granted Emergency IND by FDA for Expanded Patient Access to JadiCell(TM) Universal Donor Stem Cell for COVID-19 ARDS Outside of Ongoing Phase III Clinical Trial
Therapeutic Solutions International announced today granting of Emergency IND# 28685 and a" May Proceed Notification" from the Food and Drug Administration for the treatment of advanced COVID-19 ARDS outside of the currently ongoing Double Blind Placebo Controlled Phase III clinical trial for the same indication. James Veltmeyer, Chief Medical Officer...
RHEA-AI
neutral
05/27/22 9:00 AM
OTC : TSOI
John Hopkin's University Publishes Efficacy of QuadraMune(TM) Ingredient Sulforaphane at Inhibiting Coronavirus in Laboratory Studies
Therapeutic Solutions International, a clinical-stage biotechnology company, commented today on a recent research report from John Hopkins Children's Center in the peer-reviewed publication Nature journal Communications Biology 1. Data generated by the researchers independent of Therapeutic Solutions International, unequivocally demonstrated...
RHEA-AI
neutral